Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
The purpose of this study is to evaluate the efficacy and safety of venetoclax combined with azacitidine regimen for newly diagnosed T-ALL patients.
Trial Details
- NCT ID
- NCT05376111
- Phase
- PHASE2
- Sponsor
- The First Affiliated Hospital of Soochow University
- Status
- RECRUITING
- Cancer Type
- Acute Lymphoblastic (ALL) Leukemia
- Interventions
- Locations (sample)
- Suzhou, Jiangsu, China|31.30408,120.59538
Key Eligibility Criteria
- Patients aged ≥ 15.
- Patients diagnosed with T-ALL according to 2016 WHO criteria for precursor lymphoid neoplasms.
- ECOG performance status score less than 3.
- Patients without serious heart, lung, liver, or kidney dysfunction.
For full eligibility, visit ClinicalTrials.gov.